 Breelyn Wilky
Concepts (255)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Sarcoma | 21 | 2025 | 188 | 7.750 |
Why?
| | Soft Tissue Neoplasms | 9 | 2024 | 115 | 3.030 |
Why?
| | Gastrointestinal Stromal Tumors | 5 | 2024 | 38 | 1.920 |
Why?
| | Immunotherapy | 10 | 2023 | 641 | 1.630 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 6 | 2025 | 1692 | 1.600 |
Why?
| | Sarcoma, Alveolar Soft Part | 2 | 2023 | 6 | 1.440 |
Why?
| | Molecular Targeted Therapy | 6 | 2019 | 411 | 1.420 |
Why?
| | Bone Neoplasms | 8 | 2025 | 247 | 1.360 |
Why?
| | Hemangiosarcoma | 2 | 2021 | 21 | 1.270 |
Why?
| | Precision Medicine | 3 | 2024 | 429 | 1.060 |
Why?
| | Neoplasm Recurrence, Local | 4 | 2025 | 1079 | 0.970 |
Why?
| | Biomarkers, Tumor | 8 | 2022 | 1276 | 0.960 |
Why?
| | Antineoplastic Agents | 8 | 2023 | 2129 | 0.950 |
Why?
| | CTLA-4 Antigen | 1 | 2025 | 99 | 0.910 |
Why?
| | Circulating Tumor DNA | 2 | 2022 | 34 | 0.780 |
Why?
| | Leiomyosarcoma | 1 | 2022 | 28 | 0.770 |
Why?
| | Pyrimidines | 2 | 2018 | 470 | 0.760 |
Why?
| | Sulfonamides | 2 | 2018 | 513 | 0.750 |
Why?
| | Sarcoma, Ewing | 2 | 2025 | 97 | 0.640 |
Why?
| | Antibodies, Monoclonal, Humanized | 5 | 2025 | 804 | 0.640 |
Why?
| | Immunomodulation | 2 | 2019 | 98 | 0.620 |
Why?
| | Antineoplastic Agents, Immunological | 3 | 2019 | 190 | 0.590 |
Why?
| | Salvage Therapy | 1 | 2019 | 142 | 0.580 |
Why?
| | Humans | 58 | 2025 | 137585 | 0.530 |
Why?
| | Neoplasms | 5 | 2024 | 2671 | 0.520 |
Why?
| | Medical Oncology | 3 | 2025 | 289 | 0.500 |
Why?
| | Neovascularization, Pathologic | 1 | 2017 | 301 | 0.460 |
Why?
| | DEAD-box RNA Helicases | 1 | 2015 | 76 | 0.460 |
Why?
| | Chondrosarcoma | 3 | 2023 | 16 | 0.450 |
Why?
| | Diffusion Magnetic Resonance Imaging | 1 | 2015 | 153 | 0.430 |
Why?
| | Solitary Fibrous Tumors | 1 | 2013 | 5 | 0.420 |
Why?
| | Thoracic Neoplasms | 1 | 2013 | 37 | 0.410 |
Why?
| | Giant Cell Tumor of Tendon Sheath | 2 | 2024 | 4 | 0.410 |
Why?
| | Programmed Cell Death 1 Receptor | 2 | 2025 | 249 | 0.400 |
Why?
| | Prognosis | 7 | 2022 | 4030 | 0.400 |
Why?
| | Liposarcoma | 2 | 2023 | 27 | 0.400 |
Why?
| | Combined Modality Therapy | 6 | 2025 | 1236 | 0.380 |
Why?
| | Sarcoma, Synovial | 2 | 2024 | 21 | 0.380 |
Why?
| | Giant Cell Tumor of Bone | 2 | 2021 | 6 | 0.360 |
Why?
| | Magnetic Resonance Imaging | 3 | 2021 | 3566 | 0.330 |
Why?
| | Adult | 20 | 2025 | 37929 | 0.330 |
Why?
| | Bone Density Conservation Agents | 2 | 2021 | 80 | 0.330 |
Why?
| | Brain Neoplasms | 1 | 2019 | 1238 | 0.320 |
Why?
| | Antigens, Neoplasm | 2 | 2024 | 319 | 0.320 |
Why?
| | Doxorubicin | 2 | 2025 | 362 | 0.290 |
Why?
| | Receptor, Platelet-Derived Growth Factor alpha | 2 | 2019 | 44 | 0.280 |
Why?
| | Protein Kinase Inhibitors | 4 | 2024 | 916 | 0.280 |
Why?
| | Middle Aged | 15 | 2025 | 33479 | 0.280 |
Why?
| | Male | 19 | 2025 | 67762 | 0.270 |
Why?
| | Treatment Outcome | 10 | 2024 | 10811 | 0.270 |
Why?
| | Aged | 12 | 2025 | 23961 | 0.260 |
Why?
| | Female | 19 | 2025 | 73304 | 0.240 |
Why?
| | Indazoles | 2 | 2018 | 69 | 0.240 |
Why?
| | Liquid Biopsy | 2 | 2022 | 14 | 0.230 |
Why?
| | Isocitrate Dehydrogenase | 2 | 2015 | 59 | 0.230 |
Why?
| | DNA-Activated Protein Kinase | 1 | 2024 | 17 | 0.230 |
Why?
| | Receptors, Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2024 | 15 | 0.230 |
Why?
| | Hemangioendothelioma, Epithelioid | 1 | 2024 | 6 | 0.220 |
Why?
| | Oncologists | 1 | 2025 | 38 | 0.220 |
Why?
| | Osteosarcoma | 1 | 2025 | 74 | 0.220 |
Why?
| | Denosumab | 2 | 2021 | 9 | 0.220 |
Why?
| | Imidazoles | 2 | 2015 | 238 | 0.220 |
Why?
| | Liposarcoma, Myxoid | 1 | 2024 | 10 | 0.220 |
Why?
| | Sodium Tetradecyl Sulfate | 1 | 2024 | 2 | 0.220 |
Why?
| | Electroporation | 1 | 2024 | 38 | 0.220 |
Why?
| | Mutation | 5 | 2025 | 3958 | 0.220 |
Why?
| | Imatinib Mesylate | 1 | 2024 | 79 | 0.210 |
Why?
| | Receptors, TNF-Related Apoptosis-Inducing Ligand | 1 | 2023 | 30 | 0.210 |
Why?
| | Cancer Vaccines | 3 | 2019 | 172 | 0.200 |
Why?
| | Tetrahydronaphthalenes | 1 | 2023 | 29 | 0.200 |
Why?
| | Young Adult | 9 | 2025 | 13209 | 0.200 |
Why?
| | Job Satisfaction | 1 | 2025 | 218 | 0.200 |
Why?
| | Anemia | 1 | 2024 | 170 | 0.190 |
Why?
| | Neoplasm Metastasis | 3 | 2024 | 658 | 0.190 |
Why?
| | Cytotoxicity, Immunologic | 2 | 2019 | 224 | 0.190 |
Why?
| | Neoplasms, Second Primary | 1 | 2023 | 118 | 0.190 |
Why?
| | Thrombocytopenia | 1 | 2024 | 200 | 0.190 |
Why?
| | Academic Medical Centers | 1 | 2025 | 512 | 0.180 |
Why?
| | Survival Rate | 2 | 2019 | 1972 | 0.180 |
Why?
| | Response Evaluation Criteria in Solid Tumors | 1 | 2021 | 18 | 0.180 |
Why?
| | Quinazolines | 1 | 2023 | 251 | 0.180 |
Why?
| | Postoperative Complications | 1 | 2013 | 2654 | 0.180 |
Why?
| | Translocation, Genetic | 2 | 2019 | 105 | 0.180 |
Why?
| | Clinical Trials, Phase II as Topic | 3 | 2019 | 76 | 0.180 |
Why?
| | Tumor Microenvironment | 3 | 2019 | 674 | 0.170 |
Why?
| | beta Catenin | 1 | 2022 | 253 | 0.170 |
Why?
| | Osteoblasts | 1 | 2021 | 126 | 0.160 |
Why?
| | Chromosomes, Human, Pair 12 | 1 | 2019 | 21 | 0.160 |
Why?
| | Chromosomes, Human, Pair 7 | 1 | 2019 | 18 | 0.160 |
Why?
| | Zinc Finger Protein GLI1 | 1 | 2019 | 25 | 0.160 |
Why?
| | Gene Fusion | 1 | 2019 | 27 | 0.160 |
Why?
| | Retrospective Studies | 6 | 2024 | 15657 | 0.160 |
Why?
| | Oncogene Fusion | 1 | 2019 | 13 | 0.160 |
Why?
| | Chemoradiotherapy | 1 | 2021 | 225 | 0.160 |
Why?
| | Neoplasm Staging | 4 | 2018 | 1389 | 0.160 |
Why?
| | Vascular Endothelial Growth Factor Receptor-2 | 1 | 2019 | 86 | 0.160 |
Why?
| | Gene Amplification | 1 | 2019 | 104 | 0.150 |
Why?
| | Tumor Escape | 1 | 2019 | 42 | 0.150 |
Why?
| | Animals | 10 | 2024 | 36940 | 0.150 |
Why?
| | Transcriptome | 1 | 2025 | 971 | 0.150 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2022 | 539 | 0.150 |
Why?
| | Cell Line, Tumor | 5 | 2024 | 3412 | 0.150 |
Why?
| | Costimulatory and Inhibitory T-Cell Receptors | 1 | 2018 | 7 | 0.150 |
Why?
| | Neurofibrosarcoma | 1 | 2018 | 7 | 0.140 |
Why?
| | Carcinogenesis | 1 | 2019 | 217 | 0.140 |
Why?
| | Liver Neoplasms | 1 | 2024 | 786 | 0.140 |
Why?
| | T-Lymphocytes | 3 | 2024 | 1996 | 0.140 |
Why?
| | Receptor Protein-Tyrosine Kinases | 1 | 2019 | 234 | 0.140 |
Why?
| | Hematology | 1 | 2017 | 20 | 0.140 |
Why?
| | Melanoma | 1 | 2024 | 760 | 0.140 |
Why?
| | Radiography | 2 | 2021 | 822 | 0.140 |
Why?
| | Actins | 1 | 2019 | 416 | 0.140 |
Why?
| | Follow-Up Studies | 2 | 2019 | 5131 | 0.130 |
Why?
| | Drug Administration Schedule | 1 | 2019 | 786 | 0.130 |
Why?
| | T-Lymphocyte Subsets | 1 | 2019 | 417 | 0.130 |
Why?
| | Rhabdoid Tumor | 1 | 2018 | 99 | 0.130 |
Why?
| | Colorectal Neoplasms | 1 | 2024 | 806 | 0.130 |
Why?
| | Clinical Trials as Topic | 1 | 2021 | 1050 | 0.130 |
Why?
| | Immunotherapy, Adoptive | 1 | 2019 | 327 | 0.120 |
Why?
| | Glutarates | 1 | 2015 | 10 | 0.120 |
Why?
| | Benzeneacetamides | 1 | 2015 | 7 | 0.120 |
Why?
| | Drug Discovery | 1 | 2017 | 142 | 0.120 |
Why?
| | Simulation Training | 1 | 2017 | 106 | 0.120 |
Why?
| | Azepines | 1 | 2015 | 90 | 0.120 |
Why?
| | Disease Management | 1 | 2019 | 628 | 0.110 |
Why?
| | Aged, 80 and over | 5 | 2024 | 7635 | 0.110 |
Why?
| | Drug Monitoring | 1 | 2016 | 218 | 0.110 |
Why?
| | Receptor, IGF Type 1 | 1 | 2014 | 65 | 0.110 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 3 | 2024 | 210 | 0.110 |
Why?
| | Gene Knockdown Techniques | 1 | 2015 | 327 | 0.110 |
Why?
| | MAP Kinase Kinase Kinases | 1 | 2014 | 73 | 0.110 |
Why?
| | Paired Box Transcription Factors | 1 | 2014 | 46 | 0.110 |
Why?
| | Tomography, X-Ray Computed | 1 | 2024 | 2691 | 0.110 |
Why?
| | Apoptosis | 3 | 2023 | 2553 | 0.110 |
Why?
| | Fellowships and Scholarships | 1 | 2017 | 306 | 0.110 |
Why?
| | Chordoma | 1 | 2013 | 14 | 0.110 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2017 | 412 | 0.100 |
Why?
| | Ovarian Neoplasms | 1 | 2019 | 565 | 0.100 |
Why?
| | Macrophages | 1 | 2021 | 1547 | 0.100 |
Why?
| | Benzimidazoles | 1 | 2014 | 170 | 0.100 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2016 | 350 | 0.100 |
Why?
| | Clinical Trials, Phase III as Topic | 1 | 2013 | 106 | 0.100 |
Why?
| | Drug Screening Assays, Antitumor | 1 | 2013 | 194 | 0.100 |
Why?
| | Membrane Proteins | 1 | 2019 | 1164 | 0.100 |
Why?
| | Rhabdomyosarcoma | 1 | 2014 | 72 | 0.100 |
Why?
| | Forkhead Transcription Factors | 1 | 2014 | 191 | 0.100 |
Why?
| | Antibodies, Monoclonal | 2 | 2023 | 1430 | 0.100 |
Why?
| | Disease-Free Survival | 1 | 2014 | 686 | 0.100 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2018 | 801 | 0.100 |
Why?
| | Genetic Predisposition to Disease | 2 | 2019 | 2426 | 0.100 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2015 | 872 | 0.100 |
Why?
| | Gene Expression Regulation, Neoplastic | 2 | 2015 | 1396 | 0.100 |
Why?
| | HLA-A Antigens | 2 | 2024 | 55 | 0.090 |
Why?
| | Connective Tissue | 2 | 2022 | 36 | 0.090 |
Why?
| | Enzyme Inhibitors | 1 | 2015 | 840 | 0.090 |
Why?
| | Oncogene Proteins, Fusion | 1 | 2014 | 215 | 0.090 |
Why?
| | Angiogenesis Inhibitors | 1 | 2013 | 229 | 0.090 |
Why?
| | Sirolimus | 1 | 2013 | 276 | 0.090 |
Why?
| | Curriculum | 1 | 2017 | 992 | 0.080 |
Why?
| | Mice | 5 | 2024 | 17787 | 0.080 |
Why?
| | Immunohistochemistry | 3 | 2021 | 1738 | 0.080 |
Why?
| | NF-kappa B | 1 | 2013 | 691 | 0.080 |
Why?
| | Clinical Trials, Phase I as Topic | 2 | 2019 | 50 | 0.080 |
Why?
| | Consensus | 2 | 2022 | 683 | 0.070 |
Why?
| | Neoplasm Grading | 2 | 2018 | 307 | 0.070 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2013 | 1477 | 0.070 |
Why?
| | Receptor, Macrophage Colony-Stimulating Factor | 1 | 2024 | 11 | 0.060 |
Why?
| | Chromones | 1 | 2024 | 44 | 0.060 |
Why?
| | Career Mobility | 1 | 2025 | 69 | 0.060 |
Why?
| | Ifosfamide | 1 | 2024 | 37 | 0.060 |
Why?
| | Adolescent | 4 | 2021 | 21513 | 0.050 |
Why?
| | Microsatellite Instability | 1 | 2024 | 42 | 0.050 |
Why?
| | Anilides | 1 | 2024 | 73 | 0.050 |
Why?
| | DNA Copy Number Variations | 1 | 2025 | 182 | 0.050 |
Why?
| | Morpholines | 1 | 2024 | 122 | 0.050 |
Why?
| | Cohort Studies | 1 | 2014 | 5742 | 0.050 |
Why?
| | Frameshift Mutation | 1 | 2023 | 32 | 0.050 |
Why?
| | Activating Transcription Factor 4 | 1 | 2023 | 20 | 0.050 |
Why?
| | Proteasome Inhibitors | 1 | 2023 | 46 | 0.050 |
Why?
| | Microsatellite Repeats | 1 | 2024 | 168 | 0.050 |
Why?
| | Gene Expression Profiling | 2 | 2025 | 1774 | 0.050 |
Why?
| | Quinolines | 1 | 2024 | 178 | 0.050 |
Why?
| | Workload | 1 | 2025 | 167 | 0.050 |
Why?
| | Proto-Oncogene Proteins c-mdm2 | 1 | 2023 | 65 | 0.050 |
Why?
| | Disease Progression | 2 | 2022 | 2757 | 0.050 |
Why?
| | Valine | 1 | 2023 | 82 | 0.050 |
Why?
| | Amyloid Precursor Protein Secretases | 1 | 2023 | 80 | 0.050 |
Why?
| | Proteasome Endopeptidase Complex | 1 | 2023 | 156 | 0.050 |
Why?
| | Cell Differentiation | 2 | 2021 | 1991 | 0.050 |
Why?
| | Chemical and Drug Induced Liver Injury | 1 | 2023 | 137 | 0.050 |
Why?
| | Observational Studies as Topic | 1 | 2022 | 117 | 0.050 |
Why?
| | Gastrointestinal Hemorrhage | 1 | 2022 | 132 | 0.050 |
Why?
| | Killer Cells, Natural | 1 | 2025 | 449 | 0.050 |
Why?
| | Neoplasm Proteins | 1 | 2024 | 434 | 0.040 |
Why?
| | Cytokines | 2 | 2019 | 2085 | 0.040 |
Why?
| | T-Cell Antigen Receptor Specificity | 1 | 2019 | 50 | 0.040 |
Why?
| | Genomics | 1 | 2025 | 795 | 0.040 |
Why?
| | Mice, Nude | 1 | 2021 | 698 | 0.040 |
Why?
| | Reactive Oxygen Species | 1 | 2022 | 622 | 0.040 |
Why?
| | Prospective Studies | 2 | 2022 | 7604 | 0.040 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2023 | 528 | 0.040 |
Why?
| | Cross-Over Studies | 1 | 2021 | 564 | 0.040 |
Why?
| | Cell Lineage | 1 | 2021 | 350 | 0.040 |
Why?
| | Oncolytic Viruses | 1 | 2018 | 8 | 0.040 |
Why?
| | Organ Sparing Treatments | 1 | 2018 | 34 | 0.040 |
Why?
| | Oncolytic Virotherapy | 1 | 2018 | 14 | 0.040 |
Why?
| | Double-Blind Method | 1 | 2023 | 1993 | 0.040 |
Why?
| | Margins of Excision | 1 | 2018 | 50 | 0.040 |
Why?
| | SMARCB1 Protein | 1 | 2018 | 31 | 0.040 |
Why?
| | Radiotherapy, Adjuvant | 1 | 2018 | 220 | 0.030 |
Why?
| | Mice, Knockout | 1 | 2024 | 3015 | 0.030 |
Why?
| | SEER Program | 1 | 2018 | 227 | 0.030 |
Why?
| | Syndrome | 1 | 2018 | 358 | 0.030 |
Why?
| | DNA-Binding Proteins | 1 | 2024 | 1502 | 0.030 |
Why?
| | Germ-Line Mutation | 1 | 2018 | 172 | 0.030 |
Why?
| | Pedigree | 1 | 2018 | 514 | 0.030 |
Why?
| | Cell- and Tissue-Based Therapy | 1 | 2017 | 81 | 0.030 |
Why?
| | Models, Molecular | 1 | 2021 | 1570 | 0.030 |
Why?
| | Rats, Sprague-Dawley | 1 | 2021 | 2486 | 0.030 |
Why?
| | Immune System | 1 | 2017 | 177 | 0.030 |
Why?
| | Surgical Procedures, Operative | 1 | 2018 | 259 | 0.030 |
Why?
| | Risk | 1 | 2018 | 912 | 0.030 |
Why?
| | Receptors, Antigen, T-Cell | 1 | 2019 | 718 | 0.030 |
Why?
| | Population Surveillance | 1 | 2018 | 482 | 0.030 |
Why?
| | Incidence | 1 | 2021 | 2804 | 0.030 |
Why?
| | PAX3 Transcription Factor | 1 | 2014 | 17 | 0.030 |
Why?
| | Radiation | 1 | 2014 | 24 | 0.030 |
Why?
| | Forkhead Box Protein O1 | 1 | 2014 | 33 | 0.030 |
Why?
| | Cell Proliferation | 1 | 2021 | 2475 | 0.030 |
Why?
| | Mutation, Missense | 1 | 2015 | 341 | 0.030 |
Why?
| | Cell Cycle Checkpoints | 1 | 2014 | 98 | 0.030 |
Why?
| | Chondrocytes | 1 | 2015 | 212 | 0.030 |
Why?
| | Transplantation, Heterologous | 1 | 2013 | 194 | 0.030 |
Why?
| | Program Evaluation | 1 | 2017 | 898 | 0.030 |
Why?
| | Education, Medical, Graduate | 1 | 2017 | 486 | 0.020 |
Why?
| | Rats | 1 | 2021 | 5647 | 0.020 |
Why?
| | Sensitivity and Specificity | 1 | 2016 | 1946 | 0.020 |
Why?
| | Communication | 1 | 2017 | 879 | 0.020 |
Why?
| | Phenotype | 1 | 2019 | 3196 | 0.020 |
Why?
| | Quality of Life | 1 | 2023 | 2892 | 0.020 |
Why?
| | Disease Models, Animal | 1 | 2021 | 4295 | 0.020 |
Why?
| | Polymerase Chain Reaction | 1 | 2013 | 1062 | 0.020 |
Why?
| | Adaptation, Physiological | 1 | 2014 | 553 | 0.020 |
Why?
| | Recurrence | 1 | 2013 | 1060 | 0.020 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2017 | 1329 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2013 | 2057 | 0.020 |
Why?
| | Genotype | 1 | 2013 | 1916 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2016 | 3284 | 0.020 |
Why?
| | Biomarkers | 1 | 2019 | 4149 | 0.020 |
Why?
| | United States | 1 | 2025 | 14841 | 0.020 |
Why?
| | Child | 2 | 2019 | 21935 | 0.020 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2013 | 2189 | 0.020 |
Why?
| | Surveys and Questionnaires | 1 | 2017 | 5778 | 0.010 |
Why?
| | Child, Preschool | 1 | 2019 | 11074 | 0.010 |
Why?
| | Infant | 1 | 2018 | 9465 | 0.010 |
Why?
|
|
Wilky's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|